Australia's largest stock trading and investment forum Australia's #1 stock forum

IHL

Click for more information

0.00%

4.1¢ incannex healthcare limited

Industry news, page-416

First 416 Last

Share
Profile

Follow
Badvet73

900 Posts.

207

09/01/22

12:41

Post #: 58733265
Share

Originally posted by comincon: ↑

Psychedelic assisted therapy....
What value Part 1 and Part 2 '...different lens' presentations..... I suspect a lot of punters may think and ask this question?

What is the long term intrinsic company worth to IHL and their research association with Dr Paul and the psilocybin GAD psychedelic therapeutic assisted treatment research they are undertaking.....?

I believe it is profound and a world first in may respects - the potential in this space is a many multiple SP increase unlock as these trials and research and development progress to trial and through the FDA if approvals are forthcoming= $$$$$

Indeed IHL's intended prospectus goes to the heart of the matter and states exactly that for the keen eyed looking for long term value and exponential returns in/from their investment in IHL.

from the said prospectus
'We are also developing a treatment for generalized anxiety disorder (“GAD”) utilizing psilocybin combined with innovative psychotherapy methods.'

and'Psilocybin is a schedule I substance but there is substantial peer reviewed literature to support that there is a low chance for abuse. It is expected that once the FDA approves a psilocybin drug product, such as our drug candidate targeting GAD, this will trigger a rescheduling.'well not only/just developing treatments with innovative psychotherapy treatments but....Monashs' Neuro mind discovery centre is a 'worlds first' academic centre that addresses the entire supply chain issue in these psycedelic assisted therapies from end to end.....don't let the importance of that fact escape you in the mushroom space.....its many multiples of value add in treatment outcomes / best practice and new standard of care treatments globally.......yep - globally!

Others are testing singular psycedelic and non psychedelic drugs for particular indications and outcomes to classify the drug for the treatment regime application, no one is doing what these guys are doing at Monash....= unlocking long term intrinsic value for the investor at many multiples of the current SP - this is a differentiation that has profound significance in the psychedelic pschyatric treatment space in my view......who else is taking this approach? no one as far as I can see.....differentiation of this sort = $$$$$$$ exponential investor and investment return going forward.
remember that phrase in the presentation 'discovering, formulating, developing and progressing drug candidates to clinical trial'

So specifically to IHLs' psilocybin drug research and development with Dr Paul.....
well, this is not an island research program - simply dealing with one psychedelic and one potential indication treatment pathway....no.... by being associated with and the research progressing in tandem with the MDMA trauma and PTSD research program you are looking at a unified therapeutic treatment based approach that meets the patient unmet need end to end and develops a 'tailored' short course treatment regime of intervention with psilocybin for 'generalised anxiety disorder' (GAD) that unlocks the treatment pathway to underlying root cause trauma related PTSD through non classic psychedlics such as MDMA as per this pathway undertaken by Monsah and set up by Dr Paul.....again the MDMA proposed treatment regime is short course intervention for sustained long term therapeutic outcomes / benefits without the need to regress to long course opiates/ medications that have demonstrated poor long term outcomes and debilitating side effects over time.

For IHL and their psilocybin drug development program with Dr Paul...well it meets all the criteria this exceptional BOD continues to pursue....world first - best in class therapeutic psychedelic assisted treatment program and initiates NEW standard of care practices in psychiatric treatment programs that will, if successful trigger the rescheduling of psilocybin by the FDA.

these are my simplistic takeaways from Part 1 and Part 2 in light of what we know about IHLs' intended research pathway to rescheduling and approvals with the FDA .....

happy holder here patiently awaiting news as we all are
stress these are my own views as always
GLA

Expand

Excellent post mate. Just to throw the cat amongst the pigeons. I wonder how well our patent will hold up since challenges are starting over patenting of psilocybin. I know we are patenting the drug plus the therapy sessions but is that a strong or weak patent I wonder. Can you preclude others from copying our type of therapy sessions? What's the precedence for someone holding a unique therapy session or can it be easily copied with little chance of repercussions to the abuser of the patent? Anyone with knowledge of patents? Found this :
https://www.stellariplaw.com/post/2017/10/31/are-methods-of-psychological-treatment-patentable
and this :
https://www.vice.com/en/article/93wmxv/can-a-company-patent-the-basic-components-of-psychedelic-therapy
Not being negative, just that part worries me about being able to keep this unique and a profitable outcome

IHL Price at posting: 67.0¢ Sentiment: Hold Disclosure: Held
4 Upvote

1 Great analysis

Reply

There are more pages in this discussion • 483 more messages in this thread...

First 416 Last

Add IHL (ASX) to my watchlist

SPONSORED BY